Manufacturers: Novartis, Ionis Pharmaceuticals
Investigational antisense oligonucleotide targeting lipoprotein(a) (Lp(a)), licensed by Novartis from Ionis Pharmaceuticals. The Phase III Lp(a)HORIZON cardiovascular outcomes trial did not meet its primary endpoint.
Investigational antisense oligonucleotide targeting lipoprotein(a) (Lp(a)), licensed by Novartis from Ionis Pharmaceuticals. The Phase III Lp(a)HORIZON cardiovascular outcomes trial did not meet its primary endpoint.
Antisense oligonucleotide (ASO) that potently inhibits lipoprotein(a) (Lp(a)) production at its source.
2 associated conditions
